Kristina Jankovic, MD· @JankovicK · X·· 1 day agoScore70
Body · original
#ESMO26 🇪🇸 | FOURLIGHT-1 :
#Atirmociclib (selective CDK4i) + fulvestrant 🆚 investigator’s choice (fulvestrant or exemestane + everolimus) post-CDK4/6i:
mPFS 9.9 🆚 6.6 mo (HR 0.60)
@OncoAlert @myESMO #BreastCancer
30 views · 1 like · 1 repost · 0 replies
Conference abstracts
1842Omatched by Proffered paper 2: Breast cancer, early and advanced stage
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.orgSource: Kristina Jankovic, MD · x.com